Primitive neuroectodermal tumor

Primitive neuroectodermal tumor
Classification and external resources
ICD-O: M9473/3
DiseasesDB 31470
eMedicine ped/2589 neuro/326
MeSH D018242

Primitive neuroectodermal tumor (PNET) is a neural crest tumor.[1] It is a rare tumor, usually occurring in children and young adults under 25 years of age. After successful chemo- or(and) radio- therapy the 5 year survival rate is only 7,6-8% .[2]

It gets its name because the majority of the cells in the tumor are derived from neuroectoderm, but have not developed and differentiated in the way a normal neuron would, and so the cells appear "primitive".

PNET belongs to the Ewing family of tumors.

Contents

Classification

It is classified into two types, based on location in the body: peripheral PNET and CNS PNET.

Peripheral PNET

The peripheral PNET (pPNET) is now thought to be virtually identical to Ewing sarcoma:

"Current evidence indicates that both Ewing's sarcoma and PNET have a similar neural phenotype and, because they share an identical chromosome translocation, they should be viewed as the same tumor, differing only in their degree of neural differentiation. Tumors that demonstrate neural differentiation by light microscopy, immunohistochemistry, or electron microscopy have been traditionally labeled PNETs, and those that are undifferentiated by these analyses have been diagnosed as Ewing's sarcoma."[3]

PNET of the CNS

PNET of the CNS generally refer to supratentorial PNETs.

Survival

Patients diagnosed with a medulloblastoma or PNET are 50 times more likely to die than a matched member of the general population. The most recent population-based (Surveillance, Epidemiology and End-results Database) 5-year relative survival estimates are 64% in children (1-9 years) and 35% in adults (20+ years). [4]

Model

Using gene transfer of SV40 large T-antigen in neuronal precursor cells of rats, a brain tumor model was established. The PNETs were histologically indistinguishable from the human counterparts and have been used to identify new genes involved in human brain tumor carcinogenesis.[5] The model was used to confirm p53 as one of the genes involved in human medulloblastomas, but since only about 10% of the human tumors showed mutations in that gene, the model can be used to identify the other binding partners of SV40 Large T- antigen, other than p53.[6]

See also

References

  1. ^ "primitive neuroectodermal tumor" at Dorland's Medical Dictionary
  2. ^ [1]
  3. ^ Kumar, Vinay; Fausto, Nelso; Abbas, Abul (2004) Robbins & Cotran Pathologic Basis of Disease (7th ed.). Saunders. Page 1301. ISBN 0721601871.
  4. ^ Smoll NR "Relative Survival of Medulloblastomas and PNETs in children, adolescents and adults" Cancer (in press)
  5. ^ Eibl RH, Kleihues P, Jat PS, Wiestler OD (March 1994). "A model for primitive neuroectodermal tumors in transgenic neural transplants harboring the SV40 large T antigen". Am. J. Pathol. 144 (3): 556–64. PMC 1887088. PMID 8129041. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1887088. 
  6. ^ Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P (November 1991). "p53 mutations in nonastrocytic human brain tumors". Cancer Res. 51 (22): 6202–5. PMID 1933879. http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=1933879.